Published online Aug 16, 2021. doi: 10.4253/wjge.v13.i8.319
Peer-review started: February 18, 2021
First decision: March 14, 2021
Revised: March 21, 2021
Accepted: July 14, 2021
Article in press: July 14, 2021
Published online: August 16, 2021
Processing time: 174 Days and 23.2 Hours
Extension of lymphadenectomy during esophagectomy is on debate for adenocarcinoma of the esophagogastric junction. Thoracoscopic transthoracic access is consider superior regarding retrieved lymphonodes comparing to transhiatal esophagectomy, but overall survival is questionable.
To understand the relationship between extension of lymphadenectomy and survival according to type of surgical approach.
To compare outcomes after thoracoscopic esophagectomy and transhiatal approach for adenocarcinoma of the esophagogastric junction.
Retrospective review of medical records of patients were assessed. A total of 147 patients with adenocarcinoma of the esophagogastric junction were selected from 2002 to 2019, and divided into group A (thoracoscopic esophagectomy), and group B (transhiatal esophagectomy). Overall survival (OS), disease-free survival, post
Concerning the extent of lymphadenectomy, group A showed a higher number of retrieved lymph nodes (mean of 31.89 ± 8.2 vs 20.73 ± 7; P < 0.001), with more perioperative complications, such as hoarseness, surgical site infections, and respiratory complications. Although both groups had similar OS rates, subgroup analysis showed better survival of transthoracic esophagectomy in patients with earlier diseases.
Both methods are safe, having similar morbidity and mortality rates. Transthoracic thoracoscopic esophagectomy allows a more extensive resection of the lymph nodes and may have better oncological outcomes during earlier stages of the disease.
Prospective randomized trials addressing topics as long-term survival, the role of neoadjuvant therapies and costs.